Scopio Labs provides digital hematology imaging platforms and AI-powered analysis applications for peripheral blood smears and bone marrow aspirates. The company's technology enables clinical laboratories to fully digitize morphology workflows, view high-resolution 100x scans remotely, and collaborate across networks.
Subscribe to see Scopio Labs’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Scopio Labs is a medical devices company headquartered in Israel, founded in 2014. Its most recent funding round, Series B, raised $16M in April 2020. Xcout tracks 13 named people at Scopio Labs, including Ronen Tsimerman (Chief Financial Officer).
7 more named people on record for Scopio Labs, with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $16M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Scopio Labs's closest competitors — see the full list of competitors and alternatives →
CellaVision provides digital hematology microscopy solutions, including hardware analyzers, instruments, reagents, and specialized software applications. The company automates and streamlines workflows for human and veterinary laboratories of all sizes to analyze blood and body fluid samples.
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
Bio-View Ltd, founded in 2000 and headquartered in Rehovot, Israel, is a developer, manufacturer, and global distributor of advanced automated cell imaging and analysis systems. These sophisticated solutions are utilized by clinical and research laboratories worldwide, specifically in the fields of cytology, cytogenetics, and pathology. The company's extensive product lineup includes: Accord: A semi-automated fluorescent imaging and analysis workbench microscope station. Accord Plus: An automatic fluorescent imaging system capable of real-time scanning, analysis, and sorting of diverse FISH (Fluorescence In Situ Hybridization) samples. Allegro Plus: Another automatic fluorescent imaging system engineered to pinpoint various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. DUET-3: An imaging and analysis platform featuring an automated barcode reader, which streamlines the processing of multiple test types within a single scan batch. DeNovo: An automated scanning system dedicated to the precise detection, analysis, and characterization of circulating tumor cells found in peripheral blood. Solo Workstation & Solo Touch Workstation: These are offline and standalone workstations, respectively, providing advanced tools for reviewing and analyzing test results remotely from the microscope. SoloWeb: A comprehensive web-based solution that enables remote analysis, reporting, and expert consultation on cases scanned using Bio-View's systems. Furthermore, Bio-View Ltd has established a strategic partnership with ANGLE plc to jointly develop a liquid biopsy circulating tumor cell HER2 assay, specifically targeting breast cancer.
Sysmex Corporation, headquartered in Kobe, Japan, and established in 1968 (originally known as TOA Medical Electronics Co., Ltd. until its rebranding in October 1998), specializes in the development, manufacturing, and global distribution of advanced diagnostic instrumentation, chemical reagents, and associated software. Its comprehensive product portfolio addresses various diagnostic needs. In hematology, it offers instruments for both three-part and five-part white blood cell differentiation, alongside efficient transport systems designed for high-volume laboratory testing. For urinalysis, the company provides systems capable of analyzing urine formed sediment. Its offerings extend to automated immunochemistry systems, which are adept at performing assays with minute sample quantities, complemented by reagents for detecting infectious diseases and tumor markers. Sysmex also manufactures flow cytometers, crucial for the analysis involved in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core areas, the company is deeply involved in oncology diagnostics, developing systems for detecting cancer lymph node metastasis and cancer genome profiling, as well as offering cytogenetic testing and specialized lab assay services. Sysmex also contributes to digital medicine through the development and sale of software for diagnostic information systems, alongside the creation, operation, and maintenance of IT solutions, platforms, and applications in this field. Its activities further encompass the development and sale of nucleic acid analogs, the full lifecycle management (marketing, development, design, manufacture, sale, and after-sales support) of medical robots, and the distribution and post-sales support for medical devices and reagents used in biotechnology, medical technology, and molecular cell analysis. Sysmex serves a diverse client base, including national, public, and private hospitals, universities, research institutes, and other medical facilities. With a robust international presence, the company exports its products to approximately 190 countries worldwide. Demonstrating its commitment to innovation, Sysmex Corporation maintains a strategic alliance with QIAGEN N.V. for the collaborative development and commercialization of cancer companion diagnostics utilizing Plasma-Safe-SeqS technology.
Pensievision, Inc. is a medical imaging technology startup focused on 3D colposcopy and advanced diagnostic systems. Incorporated as a Delaware corporation, the company has received grants and funding from organizations such as the National Institutes of Health.
Medimaging Integrated Solution Inc. specializes in delivering advanced digital and mobile diagnostic technology. The company engineers and produces a variety of digital handheld diagnostic scopes, alongside their essential auxiliary equipment. A key product line is the Horus scope system, which encompasses optical coherence tomography (OCT) capabilities, integrated control units, specialized software, and a full suite of accessories. Beyond hardware, Medimaging leverages artificial intelligence for screening applications, notably in detecting diabetic retinopathy, managing wound care, and supporting general medical diagnosis. They also provide comprehensive endoscopy solutions, utilizing advanced micro camera modules to ensure superior visualization and facilitate patient-focused care. These high-performance micro camera modules are also available as standalone components. Established in 2010, Medimaging Integrated Solution Inc. maintains its headquarters in Hsinchu City, Taiwan.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.